Fresenius | FRE - Cash And Equivalent


Fresenius reported EUR1.31B in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Akzo Nobel EUR 1.62B 66M Dec/2025
Alcon AG USD 1.58B 80M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
BASF EUR 2.67B 811M Dec/2025
Bayer EUR 6.67B 774M Dec/2025
Beiersdorf EUR 1.2B 33M Dec/2025
DaVita Healthcare Partners USD 644.24M 32.2M Mar/2026
Demant DKK 1.33B 188M Dec/2025
E.ON EUR 4.87B 1.83B Mar/2026
Essilor EUR 3.54B 758M Dec/2025
Fresenius EUR 1.31B 81M Dec/2025
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
Getinge SEK 2.96B 720M Dec/2024
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GN Store Nord DKK 1.12B 352M Dec/2025
GRIFOLS EUR 801M 242.31M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Lonza CHF 719M 188M Dec/2025
Merck EUR 2.33B 77M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Philips EUR 2.79B 882M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
RWE EUR 7.73B 4.68B Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025